{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:24:19Z","timestamp":1762521859772},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ijantimicag.2015.12.008","type":"journal-article","created":{"date-parts":[[2016,1,13]],"date-time":"2016-01-13T02:05:52Z","timestamp":1452650752000},"page":"184-194","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients"],"prefix":"10.1016","volume":"47","author":[{"given":"Alejandro","family":"P\u00e9rez-Pitarch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Guglieri-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Ferriols-Lisart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilde","family":"Merino-Sanju\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0195","first-page":"331","article-title":"Sofosbuvir: a novel oral agent for chronic hepatitis C","volume":"27","author":"Cholongitas","year":"2014","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0200","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001844","article-title":"A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus","volume":"3","author":"Gross","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0210","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10928-010-9152-6","article-title":"Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation","volume":"37","author":"Ahn","year":"2010","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0215","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/infdis\/jit827","article-title":"IFNL4-\u0394G genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin","volume":"209","author":"Meissner","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0220","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/apt.12880","article-title":"Patients\u2019 preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens","volume":"40","author":"Stepanova","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0225","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1172\/JCI75938","article-title":"Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome","volume":"124","author":"Meissner","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0230","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/infdis\/jit562","article-title":"In vivo emergence of a novel mutant L159F\/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir","volume":"209","author":"Tong","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0235","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3851\/IMP2733","article-title":"Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938","volume":"19","author":"Guedj","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0240","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/jvh.12091","article-title":"All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear)","volume":"20","author":"Lawitz","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0245","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27053","article-title":"All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naive patients with genotype 1 HCV infection","volume":"60","author":"Wyles","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0250","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0255","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0260","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0265","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0270","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0275","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0280","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0285","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2013.109309","article-title":"Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial","volume":"310","author":"Osinusi","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0290","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0295","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(13)60247-0","article-title":"Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial","volume":"381","author":"Kowdley","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0300","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(13)70033-1","article-title":"Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial","volume":"13","author":"Lawitz","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0305","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0310","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.11.007","article-title":"Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection","volume":"146","author":"Gane","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0315","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0320","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2012.11.018","article-title":"Sofosbuvir (GS-7977) plus peginterferon\/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial","volume":"58","author":"Rodriguez-Torres","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0325","doi-asserted-by":"crossref","first-page":"634","DOI":"10.7326\/M14-1211","article-title":"Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study","volume":"161","author":"Osinusi","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0330","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2014.7734","article-title":"Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection","volume":"312","author":"Sulkowski","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0335","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(15)70050-2","article-title":"Ledipasvir\u2013sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)","volume":"15","author":"Bourliere","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0340","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0345","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.12.027","article-title":"The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis","volume":"148","author":"Pearlman","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0350","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/apt.12601","article-title":"Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection","volume":"39","author":"Koff","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0355","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.27366","article-title":"Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus","volume":"61","author":"Yoshida","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0360","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/qjmed\/hcu202","article-title":"Network meta-analysis of direct-acting antivirals in combination with peginterferon\u2013ribavirin for previously untreated patients with hepatitis C genotype 1 infection","volume":"108","author":"Druyts","year":"2015","journal-title":"QJM"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0365","doi-asserted-by":"crossref","first-page":"806","DOI":"10.4254\/wjh.v7.i5.806","article-title":"Impact of all oral anti-hepatitis C virus therapy: a meta-analysis","volume":"7","author":"Bansal","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0370","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.2014.7085","article-title":"Treatment of hepatitis C: a systematic review","volume":"312","author":"Kohli","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0375","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/sim.1040","article-title":"Advanced methods in meta-analysis: multivariate approach and meta-regression","volume":"21","author":"van Houwelingen","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.ijantimicag.2015.12.008_bib0380","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/clpt.2011.242","article-title":"Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond","volume":"90","author":"Mandema","year":"2011","journal-title":"Clin Pharmacol Ther"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916000030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916000030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T06:54:27Z","timestamp":1537080867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857916000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0924857916000030"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.12.008","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}